AR086186A1 - ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND - Google Patents
ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUNDInfo
- Publication number
- AR086186A1 AR086186A1 ARP120101349A AR086186A1 AR 086186 A1 AR086186 A1 AR 086186A1 AR P120101349 A ARP120101349 A AR P120101349A AR 086186 A1 AR086186 A1 AR 086186A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- subgenotypes
- population
- kit
- hcv infection
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un método de tratamiento de infección viral por hepatitis C (HCV) o alivio de uno o varios de sus síntomas en un paciente que comprende la etapa de administración al paciente de una combinación terapéutica, caracterizado porque comprende: (a) un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables; en donde B es un resto de fórmula (3); L0 es MeO-; L1 es Br; y R2 es un resto de fórmula (4); (b) un compuesto de la fórmula (2) o una de sus sales farmacéuticamente aceptables; y opcionalmente (c) ribavirina; y en donde el paciente tiene un genotipo CC o no CC de SNP rs12979860 o un genotipo TT o no TT de SNP rs 8099917 ubicado cerca del gen IL28B.Claim 1: A method of treating hepatitis C viral infection (HCV) or alleviating one or more of its symptoms in a patient comprising the stage of administration to the patient of a therapeutic combination, characterized in that it comprises: (a) a compound of the formula (1) or a pharmaceutically acceptable salt thereof; where B is a remainder of formula (3); L0 is MeO-; L1 is Br; and R2 is a residue of formula (4); (b) a compound of the formula (2) or a pharmaceutically acceptable salt thereof; and optionally (c) ribavirin; and where the patient has a CC or non-CC genotype of SNP rs12979860 or a TT or non-TT genotype of SNP rs 8099917 located near the IL28B gene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP120101349 AR086186A1 (en) | 2012-04-19 | 2012-04-19 | ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP120101349 AR086186A1 (en) | 2012-04-19 | 2012-04-19 | ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086186A1 true AR086186A1 (en) | 2013-11-27 |
Family
ID=50185256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101349 AR086186A1 (en) | 2012-04-19 | 2012-04-19 | ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR086186A1 (en) |
-
2012
- 2012-04-19 AR ARP120101349 patent/AR086186A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019000069A2 (en) | Antiviral agents against hepatitis b | |
CL2011000571A1 (en) | Use of a combination of: a) a compound of formula (1) or a pharmaceutically acceptable salt thereof, b) interferon alfa and c) ribavirin to prepare a medicament useful for the treatment of a viral infection of hepatitis c (hcv) or to relieve one or more symptoms of it. | |
EA201401281A1 (en) | D-AMINO ACID CHEMICAL COMPOUNDS FOR THE TREATMENT OF LIVER DISEASES | |
EA201170915A1 (en) | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE FOR THE TREATMENT OF VIRAL INFECTIONS | |
CR20140086A (en) | COMBINATION TREATMENTS FOR HEPATITIS C | |
EA201991174A1 (en) | COMBINATION OF TWO ANTIVIRAL DRUGS FOR TREATMENT OF HEPATITIS C | |
CO6761335A2 (en) | Hepatitis C virus inhibitors | |
EA201290993A1 (en) | NUCLEOSIDOPHOSPHORAMIDATES | |
DOP2014000049A (en) | METHODS FOR HCV TREATMENT THAT INCLUDE AT LEAST TWO DIRECT ACTION ANTIVIRAL AGENTS (DAAAS) AND RIBAVIRINE BUT NOT INTERFERONED | |
EA201290131A1 (en) | Derivatives of Purine or Deazapurine for Use in the Treatment of Viral Infections and Other Diseases | |
UY30392A1 (en) | HEPATITIS C PROTEASE INHIBITING MACROCICLIC OXIMYL COMPOUNDS | |
UY32793A (en) | INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND ITS USES | |
ECSP13012551A (en) | COMBINATION THERAPY TO TREAT HCV INFECTION. | |
EA201391685A1 (en) | HEPATITIS C VIRUS INHIBITORS | |
RU2015114543A (en) | HEPATITIS TREATMENT METHODS | |
GT201300172A (en) | INHIBITORS OF SERINE PROTEASE OF HEPATITIS C BASED ON FENANTRIDINE MACROCICILICS | |
BR112014013972A8 (en) | hcv inhibitors nssa | |
DOP2014000030A (en) | PROCEDURES FOR THE MANUFACTURE OF USEFUL DRUGS FOR THE TREATMENT OF VIRAL INFECTIONS | |
CO7131387A2 (en) | Compositions and methods of oligonucleotide chelate complex-polypeptides | |
EA201170605A1 (en) | CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE | |
EA201170484A1 (en) | THERAPEUTIC MODE OF HEPATITIS TREATMENT, INCLUDING PEG-INTERFERON, RIBAVIRIN AND VX-950 | |
BR112013024880A2 (en) | hcv treatment selection | |
RU2015114566A (en) | HEPATITIS TREATMENT METHODS | |
AR086186A1 (en) | ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A POPULATION OF SPECIFIC PATIENT SUBGENOTYPES, KIT AND COMPOUND | |
AR086185A1 (en) | ORAL COMBINED THERAPY TO TREAT HCV INFECTION IN A SPECIFIC PATIENT SUB-POPULATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |